Personalis (NASDAQ:PSNL) Reaches New 52-Week High – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) reached a new 52-week high on Tuesday . The stock traded as high as $16.15 and last traded at $15.04, with a volume of 10664380 shares trading hands. The stock had previously closed at $14.07.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. BTIG Research dropped their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday. Morgan Stanley boosted their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Personalis Stock Performance

The company has a 50-day moving average of $10.56 and a 200-day moving average of $8.80. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -15.48 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, analysts expect that Personalis, Inc. will post -1.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 435,032 shares of company stock worth $5,599,929. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Personalis in the second quarter valued at $30,000. International Assets Investment Management LLC purchased a new stake in shares of Personalis in the fourth quarter valued at $31,000. BNP Paribas Financial Markets grew its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Finally, Focus Partners Wealth acquired a new position in Personalis in the first quarter valued at $47,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.